Abstracts tagged "Osteoarthritis"

Abstract Number: 1222 • ACR Convergence 2025
Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Ahmed Abouelella¹, Mohammad Alhasan², Ahmed Hamoudah³, Ayman Ibrahim⁴, Ola O.A. Abuzied⁵, Mansoor Al-Tamimi⁶ and Muhammed Elhadi⁷, ¹Faculty of Medicine, Benha University, Benha, Al Qalyubiyah, Egypt, ²Health Education England Internal Medicine Training ( Cambridge), Cambridge, United Kingdom, ³Libyan International University, Sarasota, FL, ⁴University of Gezira, Medina, Saudi Arabia, ⁵University of Khartoum, Khartoum, Sudan, ⁶Faculty of Medicine, Cairo University, Cairo, Egypt, ⁷University of Tripoli, Huston, TX
Background/Purpose: Chronic musculoskeletal pain can be a significant source of disability and poor quality of life in adults. Many patients do not achieve adequate relief…
Abstract Number: 0335 • ACR Convergence 2025
Discontinuation and Non-Publication of Osteoarthritis Clinical Studies: A Cross-Sectional Analysis of 10,686,413 Patients
Mohamed Abdelsalam¹, Hadeer Hafez², Maryam Lasheen³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹, Abdelrahman M Hafez⁵, Omnia Samy El-Sayed⁴, Menat Alla Ayman Ali Mahdy⁴, Ali Tarek Hassanin³, Mohamed Reda Awad⁶ and Mohammed Safwat Kamal Hamza⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²⁶th October University, ⁶ october, Al Jizah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Faculty of medecine, Damietta university, Mansoura, Ad Daqahliyah, Egypt, ⁶Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt, ⁷Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt
Background/Purpose: Osteoarthritis (OA) is rising at an alarming rate, affecting millions worldwide and threatening mobility, independence, and quality of life. High-quality evidence is essential to…
Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Danielle Madison¹, Adriana Morales Rivera², Dylon Collins², Isabel Lam², Daniel Khokhar², Garrett Snyder², Anthony Thompson², Mark Soliman², Daniela Carralero Somoza² and Michael Sabina², ¹Lakeland Regional Medical Center, Lakeland, FL, ²Lakeland Regional Medical Center, Lakeland
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
Abstract Number: L04 • ACR Convergence 2024
Performance of an Artificial Intelligence Model Compared to Multiple Human Experts in Scoring Synovitis Severity and Osteophyte Severity on Joint Ultrasound Images
Anders Weber¹, Mads Ammitzbøll Danielsen², Bill Aplin Frederiksen³, Hilde Berner Hammer⁴, Benjamin Schultz Overgaard³, Lene Terslev², Thiusius Rajeeth Savarimuthu⁵ and Soren Andreas Just³, ¹ROPCA, Odense, Denmark, ²Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, ³Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, ⁴Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark
Background/Purpose: To evaluate the agreement of an artificial intelligence (AI) model designed to assess greyscale and Doppler synovitis severity and osteophyte severity in hand joints…
Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: L15 • ACR Convergence 2024
LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial
Philip Conaghan¹, Ali Guermazi², Nathaniel Katz³, Asger Bihlet⁴, Dror Rom⁵, Michael Perkins⁶, Bernadette Hughes⁶, Claire Herholdt⁶, Iwona Bombelka⁶ and Simon Westbrook⁶, ¹University of Leeds, Leeds, United Kingdom, ²Boston University, West Roxbury, MA, ³Rin Sof Innovation, Ltd, Boston, MA, ⁴NBCD A/S, Soeborg, Denmark, ⁵Prosoft Clinical, Chesterbrook, ⁶Levicept Ltd, Ramsgate, United Kingdom
Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…
Abstract Number: 0364 • ACR Convergence 2024
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Insa Mannstadt¹, J. Alex B. Gibbons² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…
Abstract Number: 1003 • ACR Convergence 2024
Association Between Metabolic Markers and Knee Osteoarthritis: A Cross-sectional Study Using the Korea National Health and Nutrition Examination Survey 2009 to 2013
Junyong Park, Minkook Son, Sang Yeob Lee, Won Tae Chung and Sung Won Lee, Dong-A University College of Medicine, Busan, Republic of Korea
Background/Purpose: Low-grade, prolonged inflammation of involved joint is characteristic of osteoarthritis (OA) pathogenesis. Thus susceptibility to inflammation has been considered as a risk factor for…
Abstract Number: 1190 • ACR Convergence 2024
Cross-sectional Associations Among Sonographic and Radiographic Features and Symptoms Scores in a Population-Based Cohort
Katherine Yates¹, Carolina Alvarez², Sahar Sawani³, Liubov Arbeeva⁴, Todd Schwartz⁵, Serena Savage-Guin⁶, Jordan Renner⁷, Catherine Bakewell⁸, Minna Kohler⁹, Janice Lin¹⁰, Jonathan Samuels¹¹ and Amanda Nelson³, ¹University of North Carolina Medical Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill, Carrboro, NC, ⁵University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁶Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill,, Chapel Hill, NC, ⁷Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Palo Alto, CA, ¹¹NYU Langone, Rye Brook, NY
Background/Purpose: Ultrasound (US) allows for visualization of features of knee osteoarthritis (KOA) including osteophytes, meniscal extrusion, synovitis, and cartilage damage. The current analysis aimed to…
Abstract Number: 1206 • ACR Convergence 2024
Association of Effusion-synovitis on Knee Pain in Early and Later-stage Knee Osteoarthritis
Lindsey MacFarlane¹, Mike Paskewicz², Jamie Collins² and Jeffrey Katz², ¹Brigham and Women's Hospital, Hanover, NH, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Pain in knee osteoarthritis (OA) is associated with structural features including effusion-synovitis (E-S) and radiographic severity. Prior studies show a cross-sectional association between larger…
Abstract Number: 1656 • ACR Convergence 2024
Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis
Katherine Escalera-Rivera, Jennifer Jonason and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Osteoarthritis (OA) is a complex disease involving pathological processes in joint tissues such as the cartilage and synovium. Cartilage is degraded by matrix metalloproteinases…
Abstract Number: 2061 • ACR Convergence 2024
Associations Between Intramyocellular Lipid and Muscle Function in Patients with Osteoarthritis
Rachel Gillcrist¹, Marianna Olave², Ryan Armbruster³ and Joshua Baker⁴, ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Intramyocellular lipids (IMCL), stored within lipid droplets in skeletal muscle cells, serve as an important metabolic fuel source during exercise. Endurance athletes have demonstrated higher…
Abstract Number: 2102 • ACR Convergence 2024
Unraveling Knee Osteoarthritis Subtypes: Differential Effect of Oral Salmon Calcitonin Treatment
Monica Hannani¹, Peder Frederiksen², Morten Karsdal², Asger Reinstrup Bihlet³, Jaume Bacardit⁴, Anne-Christine Bay-Jensen² and Christian Thudium², ¹Nordic Bioscience & University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³NBCD A/S, Soeborg, Denmark, ⁴School of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Osteoarthritis (OA) patients are to this day left without effective treatment options. Despite different etiologies, trials designs do not account for the substantial heterogeneity…
Abstract Number: PP16 • ACR Convergence 2024
Utilization of My Knee Notes for Enhanced Healthcare Management
Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA
Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
Abstract Number: 0020 • ACR Convergence 2024
CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis
Lance Murphy¹, Kevin Burt², Vu Nguyen³, Baofeng Hu², Robert Mauck³ and Carla Scanzello², ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia
Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…

« Previous Page
1
…
7
8
9
10
11
…
71
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].